News round-up for 28 August – 1 September by DDW Digital Content Editor Diana Spencer.
This week’s headline news features a stem-cell derived Parkinson’s therapy, a monoclonal antibody for head and neck cancer, an estrogen receptor degrader for breast cancer, a mitochondrial activator for long Covid, and the world’s first AI-designed bispecific T cell engager – reflecting the breadth of innovative approaches to disease being employed by researchers across the globe.
The top stories:
Stem cell derived Parkinson’s therapy shows promise
A stem cell derived investigational therapy for treating Parkinson’s disease has shown promise in early clinical trials.
FDA fast-tracks monoclonal antibody for head and neck cancer
Fast Track designation from the Food and Drug Administration (FDA) will accelerate the path to US submission for Alentis Therapeutics’ investigational monoclonal antibody.
ER degrader for breast cancer receives UK Innovation Passport
Arvinas and Pfizer UK have been awarded a UK Innovation Passport for vepdegestrant (ARV-471), an investigational PROTAC ER (estrogen receptor) degrader.
Axcella granted US patent for long Covid fatigue treatment
The US Patent and Trademark Office (USPTO) has granted a patent for Axcella Therapeutics’ long Covid treatment candidate AXA1125.
Etcembly announces immunotherapy drug designed by AI
British techbio Etcembly is coming out of stealth mode, kickstarting the next generation of immunotherapies with a pipeline of T cell receptor (TCR) therapeutics designed using generative AI.
